摘要
目的探讨利伐沙班治疗肺栓塞患者的临床疗效。方法方便选取该院2014年1月—2017年12月收治的50例肺栓塞患者作为研究对象,按照患者的入院顺序分为观察组和对照组,每组25例,其中对照组予以华法林治疗,观察组予以利伐沙班治疗,对比两组临床治疗效果。结果观察组治疗总有效率92.0%、对照组总有效率为88.0%,两组对比差异无统计学意义(χ2=0.889,P=0.346);观察组不良反应发生率为0.0%,明显低于对照组16.0%(χ2=17.391,P=0.000)。结论应用利伐沙班治疗肺栓塞具有良好的临床治疗效果,且较传统华法林治疗更安全、便捷,可替代后者用于长期抗凝治疗,值得临床应用和推广。
Objective This paper tries to explore the clinical efficacy of rivaroxaban in the treatment of pulmonary embolism. Methods 50 patients with pulmonary embolism treated in this hospital from January 2014 to December 2017 were convenient selected as the study subjects. The patients were divided into the observation group and the control group according to the admission order of the patients. Each group consisted of 25 patients. The control group was treated with warfarin. The observation group was treated with rivaroxaban and the clinical efficacy of the two groups was compared. Results The total effective rate was 92.0% in the observation group and 88.0% in the control group. There was no significant difference between the two groups（χ2=0.889, P=0.346）; the incidence of adverse reactions in the observation group was 0.0%,significantly lower than the control group 16.0%（χ2=17.391, P=0.000）. Conclusion The use of rivaroxaban in the treatment of pulmonary embolism has good clinical therapeutic effect, and is safer and more convenient than traditional warfarin therapy. It can be used as an alternative to the latter for long-term anticoagulant therapy and is worthy of clinical application and promotion.
作者
魏新玲
古力.喀德尔
WEI Xin-lin;Guli· Kadee(Department of Health,Dushanzi People＇s Hospital,Karamay,Xinjiang,833699 China;Department of Internal Medicine,Dushanzi People＇s Hospital,Karamay,Xinjiang,833699 China)
出处
《中外医疗》
2018年第16期105-106,112,共3页
China & Foreign Medical Treatment
关键词
利伐沙班
华法林
肺栓塞
Rivaroxaban
Warfarin
Pulmonary embolism
